A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)

This study tracks the safety and effectiveness of ublituximab (a drug that targets immune B cells) in older adults aged 55–80 who have relapsing forms of multiple sclerosis (MS), a group that is often underrepresented in MS clinical trials. **You may be eligible if...** - You are between 55 and 80 years old - You have relapsing MS diagnosed by standard criteria (2017 McDonald criteria) - You are about to start or have recently started ublituximab treatment (within the past 6 months) **You may NOT be eligible if...** - You are already enrolled in another interventional MS clinical trial - You received your first ublituximab dose more than 6 months ago - You had a life-threatening reaction to a previous anti-CD20 therapy (e.g., ocrelizumab, rituximab) - You have an active serious infection requiring long-term antibiotics or antifungals Talk to your doctor to see if this trial is right for you.